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Coinfection with Hepatitis C Virus among HIV-Positive
People in the Kathmandu Valley, Nepal
Krishna C. Poudel, PhD, MHSc, Paula H. Palmer, PhD,
Masamine Jimba, MD, Tetsuya Mizoue, MD, PhD,
Jun Kobayashi, MD, PhD, and Kalpana Poudel-Tandukar, PhD, MPH
Abstract
Background: Previous research has studied the rate of hepatitis C virus (HCV) coinfection among HIV-positive people regardless of their antiretroviral therapy (ART) status. Our objectives were to measure the seroprevalence of HCV both in HIV-positive
people receiving ART and in those not receiving ART and to describe the characteristics of coinfected people in the Kathmandu
Valley, Nepal. Methods: We conducted a cross-sectional survey of 319 HIV-positive people residing in the Kathmandu Valley,
Nepal. We screened the participants’ serum samples for HCV antibodies using the Latex Photometric Immunoassay based on
third-generation assay. Results: A total of 138 (43.3%) participants were HCV positive. The prevalence of HCV coinfection
was 96.2% (125 of 130) among participants with lifetime injection drug use (IDU). Among participants not receiving ART, the
coinfection rate was 58.1% (50 of 86) compared with 37.8% (88 of 233) among those receiving ART. In multivariable analysis,
participants who reported lifetime IDU and were current smokers were more likely to have HCV coinfection. The adjusted odds
ratio (AOR) of HCV coinfection for ART was decreased, although it was not statistically significant (AOR ¼ 0.45; 95% confidence
interval ¼ 0.13-1.48). Conclusion: The high prevalence of HCV coinfection among both individuals receiving ART and those
not receiving ART suggests that screening for HCV among HIV-positive people would be useful, in particular, for those with lifetime IDU and soon after their HIV diagnosis.
Keywords
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Introduction
Coinfection of the hepatitis C virus (HCV) and HIV is an
important public health concern. Of the 33.4 million HIVpositive people globally,1 around 20% are coinfected with
HCV.2 Coinfection of HCV and HIV accelerates liver disease
progression.3 Among coinfected patients, cirrhosis of the liver
is 6 times more likely compared with those infected solely with
HCV.4 The provision of antiretroviral therapy (ART) has dramatically increased the life span as well as the quality of life
for HIV-positive people both in developed and in resourcelimited countries. However, HCV-induced liver disease has
emerged as a major cause of morbidity and mortality, particularly among HIV-positive people coinfected with HCV.3,5
The management of patients coinfected with HCV and HIV
is challenging. Coinfected patients are more likely to develop
liver enzyme abnormalities and liver toxicity when treated with
ART.3 The successful treatment of HCV has been associated
with a regression of liver fibrosis6,7 and with a reduced risk of
ART-related liver toxicity.8 HIV-positive people, therefore, are
encouraged to get screened for HCV, and those with positive

results are considered for HCV treatment. Knowing that patients
are coinfected informs practitioners to provide specific education on HCV transmission and treatment, factors influencing
liver disease progression, risk reduction strategies, and risk of
reinfection.
Previous studies have assessed the prevalence of HCV
coinfection among HIV-positive people in resource-limited
countries, where the overall burden of coinfection is disproportionately high.9-13 The rate of coinfection is highly variable in these countries, ranging from 1.9% in South Africa14
and 2.4% in northern India15 to 36.2% in Brazil.9 In areas where
injection drug use (IDU) is a major route of HIV transmission,
coinfection rates of over 90% have been reported.11,15-17
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Despite the high burden of coinfection, HCV screening is
not a routine practice among HIV-positive people particularly
among those who are not eligible for ART initiation, as is the
case in most resource-limited countries. The national guidelines of these countries recommend HCV screening before the
initiation of ART.18 However, the provision of ART is still
low in some resource-limited countries19 and is even worse
among IDUs.20 Late HIV diagnosis and delayed initiation of
ART are common in these countries, resulting in elevated
morbidity and mortality.21 Since HIV and HCV share a
common route of transmission, we assume that the rates of
coinfection are similarly high among those who have initiated
ART and those who have not. However, previous studies have
reported the rate of HCV coinfection among HIV-positive
people without regard for their ART status.9,10 Gaining
knowledge about HCV coinfection among HIV-positive people, who have not yet initiated ART, would be useful to
inform the development of an HCV-screening strategy for this
group at high risk of liver disease.
We conducted this study in Nepal, a resource-limited country in South Asia. In Nepal, the first case of HIV/AIDS was
reported in 1988. Since then the HIV epidemic in the country
has advanced from ‘‘low prevalence’’ to a ‘‘concentrated epidemic,’’ with prevalence over 5% within a subgroup of mostat-risk populations. In particular, HIV prevalence among IDUs
has remained high at 6.3% in 2011 in the Kathmandu Valley,
though declining gradually over the years. HIV prevalence
among IDUs in the Kathmandu Valley was 68% in 2003 and
20.7% in 2009.22
Similar to HIV, previous studies have reported high prevalence of HCV among IDUs in the Kathmandu Valley. In a
study in 1998,23 for example, the prevalence of anti-HCV was
94% among IDUs. In 2009, another study in the Kathmandu
Valley assessed the prevalence of anti-HCV among 118 IDUs
enrolled in opioid substitution therapy (OST) and 82 IDUs who
were not in the OST program. In that study, the prevalence of
anti-HCV among the OST users and nonusers was 80.5% and
57%, respectively.24 Hepatitis C virus is known to be more rapidly transmitted by IDU than HIV.25 This suggests that the prevalence of HCV coinfection should be high particularly among
HIV-positive people with lifetime IDU in the Kathmandu Valley, regardless of their ART status. However, to date no studies
have been conducted to assess the rate of HCV coinfection
among HIV-positive people or the characteristics of coinfected
people in the Kathmandu Valley. National ART guidelines for
Nepal26 recommend screening for HCV among HIV-positive
people before ART initiation. However, specific guidelines are
still lacking for HCV screening among those HIV-positive people who are not yet eligible for ART.
The objectives of this study were to measure the seroprevalence of HCV in HIV-positive people who are receiving ART
as well as those who are not receiving ART and to describe the
characteristics of coinfected people in the Kathmandu Valley,
Nepal.

Methods
Study Area
We conducted this cross-sectional study in the Kathmandu Valley, Nepal, from February to March 2010 in the wider context
of a baseline survey of a prospective healthy living intervention
study headed by the first and the last authors.27-29 The Kathmandu Valley consists of 3 districts, namely Kathmandu, Lalitpur, and Bhaktapur, with an estimated population of 1.9 million
in 2006. In 2012, 6 of the 39 ART sites within the country were
located in the Kathmandu Valley.

Participants
We recruited a total of 322 participants for this study. The
inclusion criteria were age 18 years or older, self-reported diagnosis of HIV infection, currently living in the Kathmandu Valley, and giving written informed consent to participate in the
study. We recruited the participants through the staff of 5 nongovernmental organizations working with HIV-positive people
in the Kathmandu Valley. The procedures of the study were
reviewed and approved by the ethical committees of the Nepal
Health Research Council, Kathmandu, Nepal; National Center
for Global Health and Medicine, Tokyo, Japan; and Waseda
University, Tokyo, Japan.

Procedures
We used a structured Nepali version of the questionnaire for
data collection. First, we developed the questionnaire in
English, translated it into the Nepali language, and then back
translated it into English. After the back translation, we revised
the Nepali version again. Finally, we pretested it with 30 HIVpositive people and made additional modifications based on the
pretest results.
We hired 4 interviewers for the data collection. The first
author provided a day-long training session on the questionnaire and interview technique. The interviewers first informed
each of the participants individually about the study procedures
using an information sheet. The participants then signed the
informed consent form agreeing to participate in the study.
Subsequently, the interviewers conducted face-to-face interviews in a private setting using the structured questionnaire.
To enhance confidentiality, the interviewers reassured the
participants that codes would be used in all records instead
of their names or other identifying information. Each interview
took about 45 minutes. Participants were reimbursed 100 Nepali
rupees (about US$1.35) for their transportation costs to and from
the interview venues.
Laboratory technicians hired for the study collected approximately 10 mL of venous blood from each participant using an
evacuated tube. To separate the serum, the blood was centrifuged immediately at the interview site for 15 minutes. The
first and last authors supervised the fieldwork.
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Measures
Measures included sociodemographic and health characteristics, including age, sex, marital status, education, employment status, months since testing HIV positive, ART status,
hepatitis C status, and assessment of drug use, smoking, and
alcohol use.
We asked participants about their recent and lifetime use of
several substances including alcohol, marijuana, and others.
Alcohol use was assessed by asking participants whether they
had consumed any alcohol in the past 30 days. To assess lifetime IDU, we asked participants whether they had ever used
drugs by injection. In addition, we asked about IDU in the past
6 months. We assessed smoking status and categorized participants as current smokers if they reported smoking ‘‘every day’’
or ‘‘some days.’’30
We performed the anti-HCV test with the Latex Photometric
Immunoassay (LPIA) using test kits from Ortho HCV Abs
LPIA test III based on third-generation assay (Ortho-Clinical
Diagnostics, Tokyo, Japan).

Data Analysis
A total of 322 participants completed the structured
interview. However, 3 participants did not provide a blood
sample; thus, we included 319 participants in our analysis.
For the analysis, first, we calculated the frequencies and
descriptive statistics to summarize the general characteristics of the participants. Second, we used the chi-square test
to assess the differences in sociodemographic and health
characteristics between participants who reported lifetime IDU
and those who did not and between participants who were
receiving ART and those who were not. Third, we examined
the bivariate associations between each independent variable
and HCV coinfection among the participants. Finally, we performed multivariable logistic regression analysis to explore the
factors of HCV coinfection among the participants. We analyzed the data using SPSS version 15.0 (SPSS Inc, Chicago,
Illinois) for Windows.

Results
General Characteristics
The mean age of the participants was 35.6 years (SD ¼ 6.9
years). Of the total (n ¼ 319), 57.4% of participants were men,
68.7% were currently married, 31.7% were not employed,
73.1% were receiving ART, 40.8% reported lifetime IDU, and

Table 1. Sociodemographic and Health Characteristics of the
Participants (n ¼ 319).
Characteristics
Age, y
20-34
35-60
Sex
Female
Male
Current marital status
Single
Married
Educationa
Never been to school
Primary level (1-5 years)
Above primary level
Employment
No
Business
Office employee
Months since testing HIV positive
1-25
26-52
53-85
86-258
On antiretroviral therapy
No
Yes
Lifetime injection drug use
Yes
No
Injection drug use in past 6 months
Yes
No
Current smoking
Yes
No
Alcohol use in the past month
Yes
No
a

n (%)
182 (57.1)
137 (42.9)
136 (42.6)
183 (57.4)
100 (31.3)
219 (68.7)
58 (18.3)
70 (22.1)
189 (59.6)
101 (31.7)
65 (20.4)
153 (47.9)
81
77
81
80

(25.4)
(24.1)
(25.4)
(25.1)

86 (26.9)
233 (73.1)
130 (40.8)
189 (59.2)
27 (8.5)
292 (91.5)
150 (47.0)
169 (53.0)
40 (12.5)
279 (87.5)

Two participants did not respond to this question.

8.5% (n ¼ 27) reported IDU during the past 6 months (Table 1).
The median duration since testing HIV positive is 53 months.
Characteristics of the participants by IDU are shown in
Table 2. A higher proportion of male participants (68.3%)
reported lifetime IDU than female participants (3.7%). Similarly, educational level of the participants, antiretroviral status,
current smoking status, alcohol use, and history of sexual intercourse in the past 6 months were statistically associated with
lifetime drug use.
Characteristics of the participants by their ART status are
shown in Table 3. Fewer participants between 20 and 34 years
of age (65.4%) were receiving ART than those between 30 and
60 years of age (83.2%). Other characteristics of the participants that were statistically associated with their ART status
included sex, education level, lifetime drug use, current smoking, and alcohol use. Of the 27 participants who had endorsed
IDU in the past 6 months, 15 were not receiving ART.
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Table 2. Characteristics of the Participants by Their Lifetime Injection
Drug Use (n ¼ 319).

Table 3. Characteristics of the Participants by Their Antiretroviral
Therapy (n ¼ 319).

Lifetime History of IDU
Characteristics

Yes, n (%)

Age, y
20-34
73 (40.1)
35-60
57 (41.6)
Sex
Female
5 (3.7)
Male
125 (68.3)
Current marital status
Single
46 (46.9)
Married
84 (38.4)
Educationa
Up to primary
30 (23.4)
Secondary or above
99 (52.4)
Employment
No
35 (34.7)
Yes
95 (43.6)
Months since testing HIV positive
1-52
56 (35.4)
53-258
74 (46.0)
On antiretroviral therapy
No
46 (53.5)
Yes
84 (36.1)
Current smoking
No
23 (13.6)
Yes
107 (71.3)
Alcohol drinking
No
107 (38.4)
Yes
23 (57.5)
Had sex in the past 6 months
No
27 (29.0)
Yes
103 (45.6)

No, n (%)

On Antiretroviral Therapy
P Value

109 (59.9)
80 (58.4)

.818

131 (96.3)
58 (31.7)

<.001

54 (54.0)
135 (61.6)

.220

98 (76.6)
90 (47.6)

<.001

66 (65.3)
123 (56.4)

.143

102 (64.4)
87 (54.0)

.068

40 (46.5)
149 (63.9)

.007

146 (86.4)
43 (28.7)

<.001

172 (61.6)
17 (42.5)

.025

66 (71.0)
123 (54.4)

.008

Characteristics

Yes, n (%)

Age, y
20-34
119 (65.4)
35-60
114 (83.2)
Sex
Female
111 (81.6)
Male
122 (67.7)
Current marital status
Single
67 (67.0)
Married
166 (75.8)
Educationa
Up to primary
105 (82.0)
Secondary or above
126 (66.7)
Employment
No
72 (71.3)
Yes
171 (73.9)
Months since testing HIV positive
1-52
116 (73.4)
53-258
117 (72.7)
Lifetime injection drug use
No
149 (78.8)
Yes
83 (64.6)
Current smoking
No
137 (81.1)
Yes
96 (64.0)
Alcohol drinking
No
212 (76.0)
Yes
21 (52.5)
Had sex in the past 6 months
No
71 (76.3)
Yes
162 (71.7)

No, n (%)

P Value

63 (35.6)
23 (16.8)

<.001

25 (18.4)
61 (33.3)

.003

33 (33.0)
53 (24.2)

.105

23 (18.0)
63 (33.3)

.003

29 (28.7)
57 (26.1)

.684

42 (26.6)
44 (27.3)

.900

40 (21.2)
46 (35.4)

.007

32 (18.9)
54 (36.0)

.001

67 (24.0)
19 (47.5)

.004

22 (23.7)
64 (28.3)

.488

Abbreviation: IDU, injection drug user.
a
Two participants did not respond to this question.

a

Prevalence of HCV Coinfection

The adjusted odds ratio (AOR) of HCV coinfection for ART
was decreased, although it was not statistically significant
(AOR ¼ 0.45; 95% confidence interval ¼ 0.13-1.48). Of the
13 participants who were coinfected with HCV but did not
report lifetime IDU, 8 reported having had sexual intercourse
in the past 6 months.

A total of 138 (43.3%) participants were found to be HCV positive. The prevalence of HCV coinfection was 96.2% (125 of
130) among participants with lifetime IDU, while it was
6.9% among those without lifetime IDU. The prevalence of
HCV coinfection was 37.8% (88 of 233) among participants
receiving ART, while it was 58.1% (50 of 86) among those not
receiving ART. The prevalence of HCV coinfection was 93.3%
(14 of 15) among those participants who were not receiving
ART and had reported IDU in the past 6 months.

Factors Associated with HCV and HIV Coinfection
Factors associated with HCV coinfection among HIV-positive
participants in the bivariate analysis are shown in Table 4. In
the multivariable analysis, participants who reported lifetime
IDU were more likely to have HCV coinfection than those who
did not. Similarly, participants who were current smokers were
more likely to have HCV coinfection than those who were not.

Two participants did not respond to this question.

Discussion
This study revealed high prevalence of HCV coinfection among
HIV-positive people in the Kathmandu Valley, Nepal. Our data
indicate that more than 2 of 5 HIV-positive people had HCV
coinfection. The prevalence of coinfection was higher among
participants not receiving ART than those receiving ART though
the difference was not statistically significant in multivariable
analysis. Participants, who endorsed lifetime IDU and were
current smokers, were more likely to be coinfected with HCV.
A high proportion of HIV-positive people in this study were
coinfected with HCV. At 43.3%, the HCV coinfection rate in
our study far exceeded rates reported in India (2.4-3.5%)10,13
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Table 4. Factors Associated with HCV Coinfection among HIV-Positive People in the Kathmandu Valley, Nepal.
HCV Coinfection
Variables

Yes, n (%)

Age, y
20-34
76 (41.8)
35-60
62 (45.3)
Sex
Female
9 (6.6)
Male
129 (70.5)
Current marital status
Single
49 (49.0)
Married
89 (40.6)
Educationb
Up to primary
31 (24.2)
Secondary or above
106 (56.1)
Employment
No
35 (34.7)
Yes
103 (47.2)
Months since testing HIV positive
1-52
58 (36.7)
53-258
80 (49.7)
On antiretroviral therapy
No
50 (58.1)
Yes
88 (37.8)
Lifetime injection drug use
No
13 (6.9)
Yes
125 (96.2)
Current smoking
No
27 (16.0)
Yes
111 (74.0)
Alcohol drinking
No
115 (41.2)
Yes
23 (57.5)
Had sex in the past 6 months
No
31 (33.3)
Yes
107 (47.3)

No, n (%)

OR

(95% CI)

AORa

(95% CI)

106 (58.2)
75 (54.7)

1.15

(0.73-1.80)

1.37

(0.46-4.10)

127 (93.4)
54 (29.5)

33.71

(15.97-71.14)

2.93

(0.66-12.85)

51 (51.0)
130 (59.4)

0.71

(0.44-1.14)

0.64

(0.17-2.32)

97 (75.8)
83 (43.9)

3.99

(2.43-6.56)

2.85

(0.89-9.11)

66 (65.3)
115 (52.8)

1.68

(1.03-2.75)

2.36

(0.67-8.30)

100 (63.3)
81 (50.3)

1.70

(1.08-2.66)

1.39

(0.47-4.09)

36 (41.9)
145 (62.2)

0.43

(0.26-0.72)

0.45

(0.13-1.48)

176 (93.1)
5 (3.8)

338.46

(117.66-973.58)

142 (84.0)
39 (26.0)

14.96

(8.63-25.94)

3.58

(1.12-11.44)

164 (58.8)
17 (42.5)

1.92

(0.98-3.77)

0.57

(0.11-3.03)

62 (66.7)
119 (52.7)

1.79

(1.08-2.97)

0.46

(0.10-1.99)

169.60

(47.50-605.60)

Abbreviations: OR, odds ratio; CI, confidence interval; AOR, adjusted odds ratio; HCV, hepatitis C virus.
a
A total of 317 participants were included in the multiple logistic regression analysis (R2 ¼ 85.2).
b
Two participants did not respond to this question.

and Brazil (36.2%).9 Over 40% of participants reported a lifetime history of IDU. The HCV coinfection in this study was
markedly associated with IDU similar to previous studies31,32;
almost all (96.2%) participants who reported the lifetime history of IDU were coinfected with HCV. According to previous
research, HCV is known to be more rapidly transmitted by IDU
than HIV.25
Similarly high levels of HCV coinfection among participants receiving ART and those not receiving ART have potential implications in designing HCV-screening strategies for
HIV-positive people and in counseling those with positive test
results. Rarely do either acute or chronic HCV present with significant symptoms.33 Consequently, those infected are unlikely
to visit an HIV clinic or receive an HCV test without having
other medical problems. Infected people, who are not aware
of their HCV status, might unknowingly spread HCV to others.
In our study, for example, 15 participants who reported IDU in
the past 6 months were not receiving ART, and all except 1

were coinfected with HCV. These individuals could inadvertently transmit HCV to those with whom they share drug
paraphernalia.
In total, about 6 of the 10 participants, who were not receiving ART in our study, were coinfected with HCV. Without
innovative HCV-screening interventions, these participants are
unlikely to receive HCV testing until ART initiation. Although
HCV treatment is rare in Nepal26 like in many other resourcelimited countries,34 timely diagnosis of HCV would be beneficial in order to educate patients regarding HCV transmission,
risk of reinfection, and liver disease progression.
HIV-positive current smokers in our study were more
likely to be coinfected with HCV than nonsmokers. The high
rate of smoking among HCV coinfected HIV-positive people
in our study is a cause for concern because smoking has been
identified as a risk factor for hepatocellular carcinoma.35,36
Moreover, a meta-analysis demonstrated evidence of a synergistic effect between smoking and HCV infection on the risk
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of hepatocellular carcinoma.37 It is, therefore, important to encourage HCV-coinfected HIV-positive people to quit smoking.
An important question is how participants, who denied lifetime IDU, contracted HCV. In our study, a total of 13 HCVcoinfected HIV-positive participants did not report lifetime
IDU. Eight of these participants had had sexual intercourse in
the past 6 months. Although sexual transmission of HCV is still
controversial, traumatic intercourse may lead to a loss of mucosal barriers and may facilitate the sexual transmission of
HCV.38,39 Unfortunately, we did not measure lifetime sexual
behaviors and other important information, such as the history
of sharing razors or toothbrushes, blood transfusion, dialysis,
tattoo, and other potential modes of transmission. Further studies would be needed to address this issue.
Our study has 2 limitations. First, the diagnosis of HCV in
our study was based on anti-HCV antibody testing; HCV RNA
analysis was not performed to confirm the diagnosis. However,
it is likely that the HCV prevalence will remain high and that
the characteristics of the coinfected people will remain similar
even after confirmation of the diagnosis. This is because HCV
and HIV coinfection is associated with a reduced rate of spontaneous clearance of HCV RNA, with over 80% of patients
developing chronic infection.40 Next, as we relied on selfreported data, the responses of our participants might have been
influenced by social desirability bias, although our methodology attempted to minimize this effect.
Despite these limitations, our study documented high prevalence of HCV coinfection both among HIV-positive people
receiving ART and those not receiving ART in the Kathmandu
Valley, Nepal. It is likely that IDU was the major route of HCV
transmission among our study participants. Screening for HCV
among HIV-positive people, particularly those with lifetime
IDU and soon after their HIV diagnosis, would be useful for the
timely identification of HCV coinfection as well as education
and possibly treatment.
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